Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voruciclib (P1446A-05) in Relapsed/Refractory CLL
NCT02117336Phase 1Suspended
- Sponsor
- Piramal Enterprises Limited
- Start
- Jun 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of voruciclib in chronic lymphocytic leukemia (CLL), sponsored by Piramal Enterprises Limited. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicity. Started Jun 2014; status: suspended.
02
Drugs
voruciclib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02117336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117336.